Literature DB >> 18771493

Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: therapeutic implications for migraine.

G Martella1, C Costa, A Pisani, L M Cupini, G Bernardi, P Calabresi.   

Abstract

Cortex and periaqueductal grey (PAG) play a major role in the pathophysiology of migraine. Some antiepileptic drugs (AEDs) influence the activity of these structures by modulating high-voltage-activated (HVA) Ca(2+) channels and are effective in migraine prevention. The aim of the present study was to investigate the expression of total HVA Ca(2+) channels in cortical and PAG neurons and to study the differential action of AEDs on these channels. Isolated neurons were visually identified based on morphological criteria. HVA currents were recorded by whole-cell patch-clamp technique. The distribution ratio of L-, N-, P-, Q- and R-type HVA Ca(2+) channels was different between cortical and PAG neurons. In particular, we found that P- and Q-type HVA Ca(2+) channels were more expressed in PAG neurons than in cortical cells, whereas L- and R-type HVA Ca(2+) channels showed an opposite distribution. Interestingly, N-type HVA Ca(2+) channels were equally distributed in these two neuronal populations. A differential sensitivity to AEDs of HVA Ca(2+) channels located on cortical and PAG neurons was observed for topiramate (TPM), but not for lamotrigine (LTG) or levetiracetam (LEV). In fact, whereas both LTG and LEV were equally effective and potent in inhibiting HVA Ca(2+) currents in the two neuronal populations, TPM showed a much higher potency and efficacy in blocking these currents in PAG neurons than in cortical pyramidal cells. TPM, in fact, inhibited N-, P- and L-type channels in PAG neurons, whereas in cortical neurons this AED modulated only P- and L-type channels. Unlike the other AEDs investigated, valproic acid did not affect HVA Ca(2+) currents in cortical and PAG neurons. The negative modulation of specific subtypes of HVA Ca(2+) channels by various AEDs can restore normal electrical activity in target brain areas such as cortex and PAG, providing interesting therapeutic approaches in migraine prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771493     DOI: 10.1111/j.1468-2982.2008.01682.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

1.  Topiramate responsive exploding head syndrome.

Authors:  Gaurang M Palikh; Bradley V Vaughn
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

Review 2.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 3.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

4.  Migraine prophylaxis, ischemic depolarizations, and stroke outcomes in mice.

Authors:  Katharina Eikermann-Haerter; Jeong Hyun Lee; Nilufer Yalcin; Esther S Yu; Ali Daneshmand; Ying Wei; Yi Zheng; Anil Can; Buse Sengul; Michel D Ferrari; Arn M J M van den Maagdenberg; Cenk Ayata
Journal:  Stroke       Date:  2014-11-25       Impact factor: 7.914

5.  Formulation and evaluation of transdermal drug delivery of topiramate.

Authors:  Suneetha Cherukuri; Uma Rajeswari Batchu; Kiranmai Mandava; Vidhyullatha Cherukuri; Koteswara Rao Ganapuram
Journal:  Int J Pharm Investig       Date:  2017 Jan-Mar

6.  Sex differences in the expression of the endocannabinoid system within V1M cortex and PAG of Sprague Dawley rats.

Authors:  Aidan Levine; Erika Liktor-Busa; Austin A Lipinski; Sarah Couture; Shreya Balasubramanian; Sue A Aicher; Paul R Langlais; Todd W Vanderah; Tally M Largent-Milnes
Journal:  Biol Sex Differ       Date:  2021-11-08       Impact factor: 5.027

Review 7.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.